Core Viewpoint - Aprea Therapeutics has announced an oversubscribed private placement financing expected to generate approximately $30 million in gross proceeds for the company, aimed at supporting its research and development efforts in precision medicine oncology [1][4]. Financing Details - The private placement was led by Soleus Capital, with participation from Vestal Point Capital, Squadron Capital Management, existing investors, and certain insiders of the company [2]. - The financing will involve the sale of pre-funded warrants to purchase approximately 37.2 million shares of common stock at a price of $0.808 per warrant, and additional warrants with an exercise price of $0.683 per share [3]. Use of Proceeds - The company plans to utilize the net proceeds from the private placement for general corporate purposes and research and development expenses [4]. - Aprea aims to extend its cash runway into the first quarter of 2028, based on current business plans and assumptions [5]. Clinical Development - Aprea is focused on enrolling at least 50 patients with uterine serous carcinoma and patients with Cyclin E-overexpressing, platinum-resistant ovarian cancer in its ongoing ACESOT-1051 Phase 1 trial [5]. - The company anticipates completing dose escalation of the ACESOT-1051 trial in the second quarter of 2027 [5]. Company Overview - Aprea Therapeutics is a clinical-stage precision medicine oncology company dedicated to developing targeted therapies for biomarker-defined cancers, with a focus on exploiting vulnerabilities associated with cancer cell mutations [9]. - The company's lead programs include APR-1051, an oral small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications [9].

Core Insights - IDEAYA Biosciences is set to participate in investor relations events and has provided updated guidance on the topline data release from the Phase 2/3 OptimUM-02 trial for HLA-A2*-negative metastatic uveal melanoma [1][5] Upcoming Events - The company will host a webcast during the Bank of America Merrill Lynch Health Care Conference on May 12, 2026, featuring a fireside chat with CEO Yujiro S. Hata [2] - Another fireside chat will take place at the Stifel 2026 Targeted Oncology Virtual Forum on May 19, 2026, also featuring CEO Yujiro S. Hata [2] Company Overview - IDEAYA is focused on precision medicine in oncology, aiming to discover and develop targeted therapies for cancer [3] - The company integrates small-molecule drug discovery, structural biology, and bioinformatics to create tailored therapies aligned with genetic disease drivers [3] - IDEAYA has a pipeline that includes synthetic lethality and antibody-drug conjugates (ADCs) for solid tumor indications [3] Updated Guidance - The database lock for the OptimUM-02 trial is expected in the first half of April, with topline data analysis to follow [5]

Core Insights - IDEAYA Biosciences, Inc. is participating in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, where CEO Yujiro S. Hata will present [1] - The company focuses on precision medicine in oncology, aiming to develop targeted therapies that are tailored to the genetic drivers of cancer [2] Company Overview - IDEAYA is dedicated to the discovery, development, and commercialization of transformative cancer therapies, integrating small-molecule drug discovery, structural biology, and bioinformatics [2] - The company has a robust pipeline of product candidates, particularly in synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications [2] - The mission of IDEAYA is to create the next generation of precision oncology therapies that are more selective, effective, and personalized, with the goal of improving clinical outcomes for cancer patients [2]

Summary of IDEAYA Biosciences FY Conference Call Company Overview - **Company**: IDEAYA Biosciences (NasdaqGS:IDYA) - **Industry**: Precision medicine oncology Key Points Lead Program: Darovasertib - **Current Status**: In first-line registrational study for metastatic uveal melanoma - **Upcoming Milestones**: Randomized median progression-free survival (PFS) results expected by year-end 2025, with full enrollment for median overall survival (OS) component nearly complete, targeting over 450 patients [2][3][4] - **Breakthrough Therapy Designation**: Received for a phase 3 randomized neoadjuvant trial, which is now active with patients in screening [3][4] Patient Journey in Uveal Melanoma - **Lack of Approved Therapies**: No systemic approved therapies in neoadjuvant or adjuvant settings, with most metastatic patients also lacking approved options [5][6] - **Treatment Options**: Initial treatments include eye resection or plaque therapy, followed by adjuvant phase with no available therapies [7][8] Objectives for Neoadjuvant and Adjuvant Trials - **Primary Endpoint**: Eye preservation rate exceeding 10% with 95% confidence interval for the enucleation cohort [9][10] - **Visual Acuity Goals**: Aim for 20% or more patients in treatment arm passing a 15-letter BCVA vision test [10] DLL3 Topo ADC Program - **Efficacy Data**: Confirmed response rate of 70% in second-line small cell lung cancer at a dose of 2.4 mg/kg [15] - **Safety Profile**: Grade three or higher adverse events (AEs) below 20%, indicating potential for dose escalation [16] Future Development Plans - **Focus Areas**: Small cell lung cancer and neuroendocrine tumors (NETs) with plans to share more data in 2026 [20][23] - **MAT2A and MTAP Pathway**: Ongoing phase two trials for IDE397 (MAT2A inhibitor) and phase one for PRMT5 inhibitor, with updates expected in the first half of next year [24][25] Bispecific ADC Development - **B7-H3 and PTK7**: First-in-class bispecific ADC targeting co-expressed antigens in various tumor types, including non-small cell lung cancer and colorectal cancer [32][34] - **Patient Population**: Approximately one-third of lung cancer patients and 40%-50% of colorectal cancer patients are expected to express both antigens [34] Key Takeaways - **Upcoming Focus**: Randomized PFS results are critical for transitioning towards commercialization [38] - **Overall Strategy**: Emphasis on combination therapies and targeting co-alterations to enhance treatment efficacy [29][30] This summary encapsulates the essential insights from the IDEAYA Biosciences FY Conference Call, highlighting the company's strategic focus, ongoing clinical trials, and future development plans in the oncology sector.

Group 1 - Ideaya Biosciences, Inc. (IDYA) is a precision medicine oncology company that went public in May 2019, raising $57.5 million by issuing 5.75 million shares at $10 per share [1] - The current stock valuation of Ideaya Biosciences is $35 per share, indicating significant appreciation since its IPO [1] - The investing group Haggerston BioHealth, led by biotech consultant Edmund Ingham, provides insights and analysis on over 1,000 companies in the biotech, healthcare, and pharma sectors [1] Group 2 - Haggerston BioHealth offers catalysts for investors to monitor, along with buy and sell ratings, product sales forecasts, and integrated financial statements [1] - The group also conducts discounted cash flow analysis and market-by-market analysis for major pharmaceutical companies [1]

Core Insights - Ideaya Biosciences, Inc. (IDYA) is a precision medicine oncology company that went public in May 2019, raising $57.5 million by issuing 5.75 million shares at $10 per share, with the current stock valued at $35 per share [1] Group 1 - Ideaya Biosciences focuses on precision medicine within the oncology sector [1] - The company has been supported by a biotech consultant with over 5 years of experience in the biotech, healthcare, and pharma industries [1] - The investing group Haggerston BioHealth provides insights and forecasts for major pharmaceutical companies, including product sales and integrated financial statements [1]

Group 1 - IDEAYA Biosciences, Inc. is participating in several upcoming investor relations events, including the Cantor Global Healthcare Conference on September 3, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025 [1][2] - The company will host an R&D Day on September 8, 2025, to share clinical data updates, outline upcoming catalysts, and review its long-term portfolio strategy [1][6] - Key opinion leader Dr. Arun D. Singh will participate in the R&D Day, providing insights alongside the company's leadership team [6] Group 2 - IDEAYA is focused on precision medicine in oncology, aiming to discover and develop targeted therapies for cancer [3] - The company integrates small-molecule drug discovery, structural biology, and bioinformatics to develop tailored therapies aligned with genetic disease drivers [3] - IDEAYA has a pipeline that includes product candidates focused on synthetic lethality and antibody-drug conjugates for molecularly defined solid tumor indications [3]